Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.Products: Losartan potassium intermediate, Gabapentin intermediate, Antihypertensive drugs, Anti cancer drugs, Antiulcer drugs, Antiretroviral drugs, Antihypertensive drugs, Antiviral drugs.
Oxygenta Pharmaceutical Limited has announced a board meeting where it reviewed the financial results for the quarter ended June 30, 2025. The company reported revenue from operations of Rs 15.13 Cr, an increase from Rs 12.62 Cr in the prior year's corresponding quarter. However, the net loss for the quarter...
Oxygenta Pharmaceutical has confirmed its compliance regarding dematerialized securities for the quarter ended June 30, 2025. The company certified that all details concerning shares converted to electronic form during this period were furnished to stock exchanges. Its Registrar and Share Transfer Agent verified that securities received for dematerialization were processed...
Oxygenta Pharmaceutical Limited has announced a board meeting to discuss recent changes following a successful takeover and management change. Two Non-Executive Independent Directors, Mr. Bharath Reddy Guntuku and Mrs. Padmaja Surapureddy, have resigned due to the change in management. Both directors confirmed no other significant reasons for their resignations. This...
Oxygenta Pharmaceutical has announced a board meeting following the completion of an open offer through which Virupaksha Organics Limited became the new controlling shareholder, acquiring 55.37% of the company. The previous promoters and promoter group, holding 6.28% collectively, have been reclassified as public shareholders after transferring their shares. This shift...
Virupaksha Organics Limited has announced a board meeting on which it took control of Oxygenta Pharmaceutical Limited following a successful open offer. The new management appointed six additional directors, including three executive directors with extensive pharma experience and three independent directors with diverse backgrounds in chemistry, banking, and corporate secretarial...
